Impressive Reduction of Brain Metastasis Radionecrosis After Cabozantinib Therapy in Metastatic Renal Carcinoma: A Case Report and Review of the Literature

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Mar 24

PMID 36959812

Authors

Jacopo Lolli

Francesca Tessari

Franco Berti

Marco Fusella

Davide Fiorentin

Davide Bimbatti

Umberto Basso

Fabio Busato

Affiliations

Soon will be listed here.

Abstract

Introduction: Radionecrosis is a consequence of SRS (stereotactic radiosurgery) for brain metastases in 34% of cases, and if symptomatic (8%-16%), it requires therapy with corticosteroids and bevacizumab and, less frequently, surgery. Oncological indications are increasing and appropriate stereotactic adapted LINACs (linear accelerators) are becoming more widely available worldwide. Efforts are being made to treat brain radionecrosis in order to relieve symptoms and spare the use of active therapies.

Case Presentation: Herein, we describe a 65-year-old female patient presenting with brain radionecrosis 6 months after stereotactic radiotherapy for two brain metastatic lesions. Being symptomatic with headache and slow cognitive-motor function, the patient received corticosteroids. Because of later lung progression, the patient took cabozantinib. An impressive reduction of the two brain radionecrosis areas was seen at the brain MRI 2 months after the initiation of the angiogenic drug.

Discussion: The high incidence of radionecrosis (2/2 treated lesions) can be interpreted by the combination of SRS and previous ipilimumab that is associated with increased risk of radionecrosis. The molecular mechanisms of brain radionecrosis, and its exact duration in time, are poorly understood. We hypothesize that the antiangiogenic effect of cabozantinib may have had a strong effect in reducing brain radionecrosis areas.

Conclusion: In this clinical case, cabozantinib is associated with a fast and significant volume reduction of brain radionecrosis appearing after SRS and concomitant immunotherapy. This drug seems to show, like bevacizumab, clinical implications not only for its efficacy in systemic disease control but also in reducing brain radionecrosis. More research is needed to evaluate all molecular mechanisms of brain radionecrosis and their interaction with systemic therapies like third-generation TKIs.

References

Lee D, Riestenberg R, Haskell-Mendoza A, Bloch O . Brain Metastasis Recurrence Versus Radiation Necrosis: Evaluation and Treatment. Neurosurg Clin N Am. 2020; 31(4):575-587. DOI: 10.1016/j.nec.2020.06.007. View

Andrews D, Scott C, Sperduto P, Flanders A, Gaspar L, Schell M . Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004; 363(9422):1665-72. DOI: 10.1016/S0140-6736(04)16250-8. View

Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J . Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014; 15(4):387-95. DOI: 10.1016/S1470-2045(14)70061-0. View

Daisne J, De Ketelaere C, Jamart J . The individual risk of symptomatic radionecrosis after brain metastasis radiosurgery is predicted by a continuous function of the V12Gy. Clin Transl Radiat Oncol. 2021; 27:70-74. PMC: 7829108. DOI: 10.1016/j.ctro.2021.01.003. View

Zhang Y, Guessous F, Kofman A, Schiff D, Abounader R . XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs. 2010; 13(2):112-21. PMC: 3268517. View

Patel A, Dong T, Ansari S, Cohen-Gadol A, Watson G, Moraes F . Toxicity of Radiosurgery for Brainstem Metastases. World Neurosurg. 2018; 119:e757-e764. DOI: 10.1016/j.wneu.2018.07.263. View

Yoritsune E, Furuse M, Kuwabara H, Miyata T, Nonoguchi N, Kawabata S . Inflammation as well as angiogenesis may participate in the pathophysiology of brain radiation necrosis. J Radiat Res. 2014; 55(4):803-11. PMC: 4100008. DOI: 10.1093/jrr/rru017. View

Albiges L, Schmidinger M, Taguieva-Pioger N, Perol D, Grunwald V, Guemas E . CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma. Future Oncol. 2021; 18(8):915-926. DOI: 10.2217/fon-2021-1006. View

Pires da Silva I, Glitza I, Haydu L, Johnpulle R, Banks P, Grass G . Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell Melanoma Res. 2019; 32(4):553-563. PMC: 8258671. DOI: 10.1111/pcmr.12775. View

10.

Yakes F, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P . Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011; 10(12):2298-308. DOI: 10.1158/1535-7163.MCT-11-0264. View

11.

Milano M, Grimm J, Niemierko A, Soltys S, Moiseenko V, Redmond K . Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain. Int J Radiat Oncol Biol Phys. 2020; 110(1):68-86. PMC: 9387178. DOI: 10.1016/j.ijrobp.2020.08.013. View

12.

Heffron T . Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. J Med Chem. 2016; 59(22):10030-10066. DOI: 10.1021/acs.jmedchem.6b00618. View

13.

Peng L, Grimm J, Gui C, Shen C, Redmond K, Sloan L . Updated risk models demonstrate low risk of symptomatic radionecrosis following stereotactic radiosurgery for brain metastases. Surg Neurol Int. 2019; 10:32. PMC: 6499458. DOI: 10.4103/sni.sni_303_18. View

14.

Liniker E, Menzies A, Kong B, Cooper A, Ramanujam S, Lo S . Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology. 2016; 5(9):e1214788. PMC: 5048757. DOI: 10.1080/2162402X.2016.1214788. View

15.

Yu S, Quinn D, Dorff T . Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection. Onco Targets Ther. 2016; 9:5825-5837. PMC: 5045229. DOI: 10.2147/OTT.S97397. View

16.

Minniti G, Clarke E, Lanzetta G, Osti M, Trasimeni G, Bozzao A . Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol. 2011; 6:48. PMC: 3108308. DOI: 10.1186/1748-717X-6-48. View

17.

Kirkpatrick J, Wang Z, Sampson J, McSherry F, Herndon 2nd J, Allen K . Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: results of a randomized trial. Int J Radiat Oncol Biol Phys. 2014; 91(1):100-8. DOI: 10.1016/j.ijrobp.2014.09.004. View

18.

Kiess A, Wolchok J, Barker C, Postow M, Tabar V, Huse J . Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys. 2015; 92(2):368-75. PMC: 4955924. DOI: 10.1016/j.ijrobp.2015.01.004. View

19.

Schuttrumpf L, Niyazi M, Nachbichler S, Manapov F, Jansen N, Siefert A . Prognostic factors for survival and radiation necrosis after stereotactic radiosurgery alone or in combination with whole brain radiation therapy for 1-3 cerebral metastases. Radiat Oncol. 2014; 9:105. PMC: 4036428. DOI: 10.1186/1748-717X-9-105. View

20.

Procopio G, Claps M, Pircher C, Porcu L, Sepe P, Guadalupi V . A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03). Tumori. 2022; 109(1):129-137. PMC: 9896529. DOI: 10.1177/03008916221138881. View